Abstract Purpose: To determine whether -CONH-(CH 2 ) 6 -NH 3 + Cl À functionalized single-walled carbon nanotubes (SWNT) carrying complexed small interfering RNA (siRNA) can enter into tumor cells, wherein they release the siRNA to silence the targeted gene. Experimental Design: -CONH-(CH 2 ) 6 -NH 3 + Cl À was used to mediate the conjugation of telomerase reverse transcriptase (TERT) siRNA to SWNTs. The ability of TERT siRNA delivered via SWNTcomplexes to silence the expression of TERT was assessed by their effects on the proliferation and growth of tumor cells both in vitro and in mouse models. Results: The functionalized SWNTs -CONH-(CH 2 ) 6 -NH 3 + Cl À could facilitate the coupling of siRNAs that specifically target murine TERT expression to form the mTERT siRNA:SWNT+ complex. These functionalized SWNTs rapidly entered three cultured murine tumor cell lines, suppressed mTERT expression, and produced growth arrest. Injection of mTERT siRNA:SWNT+ complexes into s.c. Lewis lung tumors reduced tumor growth. Furthermore, human TERT siRNA:SWNT+ complexes also suppressed the growth of human HeLa cells both in vitro and when injected into tumors in nude mice. Conclusions: -CONH-(CH 2 ) 6 -NH 3 + Cl À functionalized SWNTs carry complexed siRNA into tumor cells, wherein they release the siRNA from the nanotube sidewalls to silence the targeted gene.The -CONH-(CH 2 ) 6 -NH 3 + Cl À functionalized SWNTs may represent a new class of molecular transporters applicable for siRNA therapeutics.
The ability of functionalized single-walled carbon nanotubes (SWNT) to penetrate mammalian cells without apparent cytotoxicity suggests their applicability as carriers for internalization of drugs or delivery of vaccines. Oxidized SWNTs can be functionalized at their carboxylic groups with proteins, peptide, DNA, oligonuceotide, sugar moieties, polyoxide derivatives, etc.
(1 -5). SWNTs functionalized with nucleic acids, such as small interfering RNA (siRNA) or DNA, show promise for application in gene therapy and gene interference (6) . Telomerase is the key enzyme for the stabilization of chromosomes by adding TTAGGG repeats to the telomere ends (7, 8) . Activation of telomerase is critical for immortalization and is detected in majority of malignant tumors but not in most normal somatic cells. Therefore, small-molecule inhibitors of telomerase activity or knockdown of telomerase expression represents attractive approaches for targeted cancer therapy. RNA interference (RNAi) is a powerful tool to dissect functional consequences of target inactivation in mammalian cells and model organisms (8) . Delivery of siRNA to target cells is complicated by the instability of siRNA, low uptake efficiency, and properties of their bioavailability. Thus, more efficient siRNA delivery methods are required to realize the potential of siRNA to address both basic biological questions and provide therapeutic benefit. In this study, we used -CONH-(CH 2 ) 6 -NH 3 + Cl À to mediate the conjugation of siRNA to SWNTs and examined the ability of telomerase reverse transcriptase (TERT) siRNA delivered via SWNT complexes to silence the expression of TERT and inhibit the proliferation and growth of tumor cells both in vitro and in mouse models.
Materials and Methods
Preparation of SWNTs: DNA labeled with FAM fluorescein (SWNTsdsDNA-FAM). To investigate the penetration of SWNTs in to tumor cells, SWNTs were functionalized using DNA labeled with FAM fluorescein by the procedure of Hazani et al. (9) . Functionalized SWNTs with ssDNA were characterized using transmission electron microscopy equipped with energy-dispersive X-ray spectroscopy (Tecnai 20, FEI, Hillsboro, OR) and atomic force microscopy (Nanoscope multimode scanning probe microscope, Veeco, Woodbury, NY). SWNTs bound with captured ssDNA (SWNTs-sDNA; 50 mg/L) and the target DNA labeled with FAM (27 Amol/L) were added into boiling water and then cooled to 4jC to permit annealing. After washing, the resulting functionalized SWNTs-dsDNA-FAM was used in the following experiments. The fluorescence spectrum of SWNTs-sDNA hybridized with either complementary or noncomplementary FAM-labeled DNA was assayed using a FluoroMax-P (Jobin Yvon, Edison, NJ).
siRNA design, synthesis, and transfection. The siRNA sequences used for gene silencing of mouse TERT (mTERT) were designed using the protocol described on http://www.ambion.com. Specific mTERT sequences targeted are AACAGATCAAGAGCAGTAGTC (sequence 1) and AATAT-GTCAGACTCCTCAGGT (sequence 2). Specific human TERT (hTERT) sequences targeted are AAGCACTTCCTCTACTCCTCA (sequence 1) and AACACCAAGAAGTTCATCTCC (sequence 2). The nonsilencing control siRNA is an irrelevant siRNA with random nucleotides ACUATCUAA-GUUACTACCCCTT. Sequences were synthesized and annealed.
Preparation of mTERT siRNA:SWNTs complexes mediated by -CONH-(CH 2 ) 6 -NH 3 + Cl À (mTERT siRNA:SWNTs+). SWNTs were prepared using our previously described method (10) and then purified and shortened as in Hazani et al. (9) . To prepare the positively charged SWNTs (SWNTs+), we first generated the tert-butyl N-(6-aminohexyl) carbamate (Boc-C 6 H 12 NH 2 ) using a procedure reported by Far et al. (11) . SWNT-COCl was prepared as described previously (12) from shortened SWNTs. SWNT-COCl (0.0691 g) and Boc-C 6 H 12 NH 2 (4.3 g) were then reacted in dimethylformamide at 90jC for 96 hours under argon. The SWNTs functionalized with Boc-protected amines in the previous step (SWNT-CONH-C 6 H 12 NH-Boc) were collected by filtration (0.1 Am) and washed twice with dioxane. Boc groups were removed using a procedure similar to that reported by Han et al. (13) . A solution of HCl/dioxane (0.4 mL/9.6 ml) in a 25-mL round-bottomed flask equipped with a magnetic stir bar was cooled in an ice-water bath under argon, and then SWNT-CONH-C 6 H 12 NH-Boc (30 mg) was added with stirring. The ice bath was removed, and the mixture was stirred for 1 hour. The reaction mixture was collected by centrifugation and then washed twice with dioxane. Finally, aqueous HCl solution (6 mol/L) was added into the aqueous suspension of functionalized SWNTs, and the positively charged functionalized SWNTs were collected by standard centrifugation and membrane filtration (0.1 Am). This functionalization procedure for SWNTs avoids reaction of amino groups of 1,6-diaminohexane between different SWNTs and consequent aggregation. Indeed, SWNTs functionalized using this method better disperse in water than those produced by conventional methodology. The solubilized SWNTs were mostly individual tubes (nonaggregated) and small bundles as revealed by spectrometry and atomic force microscopy, respectively. The SWNT concentration in the solution after this process was estimated at 25 mg/L. To prepare the siRNA functionalized SWNTs, the SWNT-CONH-(CH 2 ) 6 -NH 3 + (50-100 mg/L) was incubated with siRNA at 100 nmol/L for 1 hour in room temperature and then washed twice before use. The coupling of siRNA with SWNTs+ was assessed by transmission electron microscopy equipped with energy-dispersive X-ray spectroscopy, atomic force microscopy, and spectrophotometry (BioPhotometer, Eppendorf, Hamburg, Germany). University School of Medicine, Baltimore, MD), and the Beijing Animal Center (Beijing, China), respectively] in 24-well plates. Specific mTERT siRNA:SWNTs+ or control mock siRNA:SWNTs+ or siRNA alone was added into each well, and cell growth was monitored daily. The level of TERT mRNA and the expression of TERT protein were analyzed by reverse transcription-PCR and Western blotting after 48 hours. FAM-DNA-SWNT was used to transfect tumor cells using similar methods.
Reverse transcription-PCR analysis. Total cellular RNA was prepared using Trizol reagent (Invitrogen, Carlsbad, CA) followed by RNA cleanup with RNeasy Mini kit (Qiagen, Valencia, CA) as recommended by the manufacturer. Reverse transcription-PCR was done by SuperScript one-step reverse transcription-PCR with Platinum Taq according to the protocol provided (Invitrogen). The primers used include the following: mTERT, 5 ¶-ATGACCCGCGCTCCTCGTTGC and 3 ¶-GACAG-CAGAGATGTGGAGCTG; hTERT, 5 ¶-ATGCCGCGCGCTCCCCGCTG and 3 ¶-GCTCGCAGCGGGCAGTGCGT; and glyceraldehyde-3-phosphate dehydrogenase, 5 ¶-ATGGTGAAGGTCGGTGTGAACGGATTTGGC and 3 ¶-CATCGAAGGTGGAAGAGTGGGAGTTGCTGT.
Western blot analysis. 1H8, TC-1, and LLC cells or HeLa tumor cells were harvested by centrifugation for 10 minutes at 600 Â g. For Western blotting of TERT protein, nuclear extract was prepared according to a reported procedure (15) and then 100 Ag of nuclear extract were separated by 7.5% SDS-PAGE and transferred to nitrocellulose membrane. After blocking with 5% nonfat dry milk, the membrane was incubated with rabbit anti-TERT polyclonal antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA). The protein-antibody complexes were detected using the peroxidase-conjugated secondary antibody (Boehringer Mannheim, Mannheim, Germany) and enhanced chemiluminescence (Amersham, Buckinghamshire, United Kingdom). As a loading control, actin was also assessed using anti-actin antibody (2G2, STI, Darmstadt, Germany).
Telomerase activity assay. A commercial telomerase PCR ELISA kit (Boehringer Mannheim) based on the telomeric repeat application protocol introduced by Kim et al. (16) was used to determine telomerase activity.
Results and Discussion
Penetration of SWNTs-dsDNA-FAM into different mouse tumor cells. Several groups have described the ability of SWNTs to penetrate mammalian cells and to deliver cargos, such as small peptides, protein, and nucleic acid (2, 3) . Here, we examined the ability of SWNTs functionalized with FAM fluorescently labeled short dsDNA (20 bp; SWNTs-dsDNA-FAM) to enter into three murine tumor cell lines. SWNTs functionalized with aminomodified DNA (SWNTs-sDNA) were prepared, and their structure was validated by transmission electron microscopy ( Supplementary Fig. S1A1 ) and atomic force microscopy (data not shown). The presence of the fluorescently labeled short dsDNA after SWNTs-sDNA hybridized with FAM complement DNA was confirmed by fluorescence spectroscopy (Supplementary Fig. S1A2 ). When the SWNTs-dsDNA-FAM was incubated with 1H8, TC-1, and LLC tumor cells, its uptake could be clearly visualized by fluorescence microscopy at 4 hours (Supplementary Fig. S1B3 , C3, and D3) and flow cytometry ( Supplementary  Fig. S1B4 , C4, and D4). No obvious toxicity was observed grossly, consistent with previous reports (2, 17) .
Preparation of mTERT siRNA:SWNTs complexes mediated by -CONH-(CH 2 ) 6 Fig. S2A ). The binding of mTERT siRNA to oxidized SWNTs was shown by transmission electron microscopy equipped with energy-dispersive X-ray spectroscopy (Supplementary Fig. S2B ). The energydispersive X-ray spectroscopy spectrum of the siRNA:SWNTs+ complex revealed a strong elemental phosphorus-associated peak ( Supplementary Fig. S2B3 ), which is absent in the energydispersive X-ray spectroscopy spectrum of siRNA:SWNTs ( Supplementary Fig. S2B2 ) and shortened SWNTs (Supplementary Fig. S2B1 ). Spectrophotometric analysis at 260 nm also showed that SWNTs conjugated with -CONH-(CH 2 ) 6 -NH 3 + Cl À promoted the coupling of siRNA to SWNTs ( Supplementary  Fig. S2C ). Thus, positive charge functionalization not only promotes the coupling of protein and DNA with SWNTs (18) but also mediates the conjugation of siRNA with SWNTs. SWNTs mediated in vitro delivery of TERT siRNA into tumor cells to silence the TERT gene. Although SWNTs transport biological molecules in the cells with no apparent ill effects on cell viability, it is unclear whether the mTERT siRNA:SWNTs+ complexes mediated by -CONH-(CH 2 ) 6 (Fig. 1C ).
mTERT siRNA:SWNT+ complexes mediated by -CONH-(CH2)6-NH3+ClÀ suppressed the proliferation of mouse tumor cells in vitro. Telomerase is a cellular RNA-dependent DNA polymerase that maintains the tandem telomeric TTAGGG repeats at eukaryotic chromosome ends (7), and TERT is its proteinaceous catalytic subunit (19) . Thus, TERT plays a critical role in tumor development and growth through the maintenance of telomere structure. The first example of telomerasetargeted gene therapy was reported by Feng et al. (20) . Antisense RNA targeting the first 185 nucleotides of the TERT molecule was induced into HeLa cells and caused progressive telomere shortening and, eventually, cell crisis (20) . Therefore, we sought to determine the effect of TERT siRNA:SWNT+ complexes on the levels of TERT and growth of LLC, TC-1, and 1H8 tumor cells. The three cell lines were plated (0.5 Â 10 5 per well of 24-well plate) and, after an overnight incubation, treated with 2 nmol/L TERT siRNA:SWNTs+ complexes. The mTERT siRNA:SWNTs+ clearly suppressed the growth of LLC, TC-1, and 1H8 and reduced the cell number after 6 days of incubation, whereas addition of TERT siRNA alone or mock siRNA:SWNTs+ complexes did not significantly affect cell growth (Fig. 2) . The Under phase-contrast microscopy, LLC, TC-1, and 1H8 cells treated with mTERT siRNA:SWNTs+ complexes showed distinctive morphologic features associated with senescence, including growth arrest, enlargement, and a vascuolated cytoplasm (Fig. 2) . These findings were absent from the TERT siRNA alone or mock siRNA:SWNTs+ transfected control cells. Similar findings were described previously in the murine RenCa renal carcinoma line on ectopic expression of mutant mTERT (21) . Safety and biocompatibility are major concerns when introducing a gene therapy to patients. Several groups have reported that relatively pure, well-solubilized short carbon nanotubes seem nontoxic once internalized into mammalian cells. Indeed, as shown in Fig. 2 , mTERT siRNA:SWNTs+ did not adversely affect cell biology or exhibit obvious toxicity in three cell lines. (Fig. 3) ; the average tumor weight harvested at day 7 was significantly reduced compared with untreated (P < 0.0002, ANOVA) and injection of control mTERT siRNA alone or mock siRNA:SWNT+ complexes (Fig. 3) . The effectiveness of mTERT siRNA:SWNT+ complexes at multiple sites was more effective in retarding tumor growth than injection at a single point (Fig. 3A  and B) . Most tumor cells from tumor tissue injected with SWNTs-dsDNA-FAM were fluorescent, indicating penetration of SWNTs (Fig. 3D) . Furthermore, injection of mTERT siRNA:SWNT+ into tumor tissue also induced senescence as determined by measurement of the marker of senescenceassociated h-galactosidase in this but not the other treatment groups (Fig. 3E) .
Because there may be differences in the biology of telomeres and nanotube uptake in human versus murine tumor cells, we explored the potential of hTERT siRNA:SWNT+ complexes to inhibit the growth of the human cervical cancer cell line HeLa. Specific gene silencing induced by hTERT siRNA:SWNT+ complexes was observed in human HeLa cells at the transcript (Fig. 4A), protein (Fig. 4B) , and functional level (Fig. 4C) and triggered senescence as indicated by the expression of senescence-associated h-galactosidase in >80% of treated but not control cells (Fig. 4D and E) . Importantly, intralesional injection of hTERT siRNA:SWNT+ complexes significantly and specifically suppressed human HeLa cell growth versus control (Fig. 4F-H) . The transduction of both the human melanoma line LOX and the human transitional bladder carcinoma line UM-UC-3 with mutant hTERT via lentivirus also produced a rapid inhibition of cell growth, although the responses of the colon cancer line HCT116, breast cancer line MCF-7, and prostate cancer line LNCAP were slower (22) . Similarly, antisense-mediated hTERT inhibition specifically reduces the growth of the four human bladder cancer lines EJ28, 5637, J82, and HT1197 (23) . Importantly, coexpression of hTERT siRNA sensitizes tumor cells to the effects of mutant hTERT (22) . Given the rapid response of the cell lines to TERT knockdown, it is possible that telomeric shortening is not the only , mTERTsiRNA:SWNTs, siRNA alone, or mock siRNA:SWNT+ complexes were injected into tumors at a single site (100 AL of 10 nmol/L siRNA per mouse). B, LLC tumor size at day 7 after injection at multiple intralesional sites. B1, control; B2, mTERTsiRNA:SWNT+ complexes; B3, mTERTsiRNA alone; B4, mock siRNA:SWNT+ complexes. LLC tumor cells (1 Â10 6 per mouse) were injected s.c into right leg of mouse (five mice per group). After 1week, when diameter of tumor was f5 mm, mTERTsiRNA:SWNTs were injected into tumor at multiple points (100 AL of 10 nmol/L siRNA per mouse). At the same time, controls, siRNA alone, or mock siRNA:SWNT+ complexes were also injected into tumor using similar method. C, columns, mean tumor weight; bars, SE. Tumor cells from tissues injected by SWNTs-dsDNA-FAM (D4-D6) and control SWNTs (D1-D3) viewed by fluorescence microscopy (D2 and D5) and flow cytometry analysis (D3 and D6). Black line, tumor cells from uninjected tissue; red line, fluorescence intensity of tumor cells from tissue injected by SWNTs-dsDNA-FAM or control SWNTs. E, induction of senescence by mTERTsiRNA:SWNT+ after injection into tumor tissue. After mTERTsiRNA:SWNTs were injected into tumor at multiple points (100 AL of 10 nmol/L siRNA per mouse) for 6 days, senescence-associated h-galactosidase activity tumor sections from different treatment groups were measured as described previously (26) . mechanism responsible for arrest. Li et al. found that cell arrest and apoptosis on ectopic expression of mutant TERT occurs independently of p53 and with limited telomeric shortening. However, TERT knockdown is associated with changes in global gene expression profile indicative of a novel response pathway, including suppression of specific genes implicated in angiogenesis and metastasis (24) . A recent study suggests the involvement of the transforming growth factor-h signaling pathway in this response (25) .
Efficient intracellular transport and delivery of siRNA is critical to the potency and in vivo application of RNAi. Our results show that mTERT siRNA:SWNT+ complexes mediated by -CONH-(CH 2 ) 6 -NH 3 + Cl À can penetrate the tumor cells both in culture and in mice to induce the suppression of tumor cells. We provide support for the targeting of TERT in genetic therapy of cancer. However, although we chose to target mTERT in these studies, this approach can clearly be extended to other targets for RNAi. Because the functionalized SWNTs do not only enter cancer cells, we used direct intratumoral injection. Further studies are needed to assess the distribution of SWNTs after systemic i.v. administration and the potential to target undetected micrometastases. Nevertheless, specific targeting of cancer cells could be achieved in those expressing mutated, fusion, or xenogenic oncogenes, for example, knockdown of human papillomavirus-16 E6 and E7, which triggers apoptosis of cervical cancer cells. This approach might also be applicable in cancer cells that are dependent on dramatically elevated levels of a particular proto-oncogene (e.g., HER-2/neu or c-Myc).
In summary, these studies show the potential of functionalization of SWNTs with siRNA mediated by -CONH-(CH 2 ) 6 -NH 3 + Cl À for specific gene knockdown in vivo and suggest that knockdown of TERT expression using specific siRNA: SWNTs+ complexes warrants further exploration as a potential therapeutic strategy against multiple different tumor types.
